{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:59:07Z","timestamp":1792616347513,"version":"4.5.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":33,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Plaque psoriasis is a chronic debilitating condition, and biologic agents that inhibit tumor necrosis factor-\u03b1 (TNF-\u03b1) are widely employed in management of the condition. Notwithstanding, several paradoxical adverse reactions have been reported with TNF-\u03b1 inhibitors, including vasculitis, vitiligo, alopecia areata, sarcoidosis and other granulomatous diseases. Herein, we report the case of a 63-year-old man who developed vitiligo while on therapy with adalimumab following failure of conventional agents for plaque psoriasis. After discontinuation of adalimumab and initiation of secukinumab, vitiligo and other psoriatic symptoms gradually resolved. After 1\u00a0year of treatment, only small plaque areas were present in the flexor site with complete remission in the extensor area along with near complete resolution of depigmented areas. In this case of possible adalimumab-induced vitiligo in a patient with plaque psoriasis, secukinumab resolved both the symptoms of psoriasis and the likely adalimumab-related vitiligo.<\/jats:p>","DOI":"10.1093\/omcr\/omz134","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T02:57:04Z","timestamp":1581562624000},"source":"Crossref","is-referenced-by-count":23,"title":["Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris"],"prefix":"10.1093","volume":"2020","author":[{"given":"Giovanni","family":"Palazzo","sequence":"first","affiliation":[{"name":"Ambulatorio di Dermatologia, Ospedale Distrettuale di Tinchi, 75015 Pisticci, MT, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"2020021221491990400_ref1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-alpha blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"2020021221491990400_ref2","first-page":"875","article-title":"Secukinumab in the treatment of psoriasis: patient selection and perspectives","author":"Yang","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"2020021221491990400_ref3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"2020021221491990400_ref4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020021221491990400_ref5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000324619","article-title":"Vitiligo during treatment of Crohn's disease with adalimumab: adverse effect or co-occurrence?","volume":"3","author":"Posada","year":"2011","journal-title":"Case Rep Dermatol"},{"key":"2020021221491990400_ref6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000081494","article-title":"Infliximab-induced vitiligo","volume":"210","author":"Ramirez-Hernandez","year":"2005","journal-title":"Dermatology"},{"key":"2020021221491990400_ref7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2020021221491990400_ref8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jaad.2011.07.018","article-title":"Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-beta) in patients with vitiligo","volume":"66","author":"Khan","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2020021221491990400_ref9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"2020021221491990400_ref10","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/bjd.13988","article-title":"Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma","volume":"173","author":"Malerba","year":"2015","journal-title":"Br J Dermatol"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2020\/1\/omz134\/32316325\/omz134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2020\/1\/omz134\/32316325\/omz134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T02:57:08Z","timestamp":1581562628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omz134\/5721283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,31]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omz134","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2020,1]]},"article-number":"omz134"}}